The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 12, 2016

Filed:

May. 22, 2014
Applicant:

Icahn School of Medicine AT Mount Sinai, New York, NY (US);

Inventors:

Peter Palese, Leonia, NJ (US);

Adolfo Garcia-Sastre, New York, NY (US);

Thomas Muster, Vienna, AT;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/145 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/145 (2013.01); A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/525 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/543 (2013.01); A61K 2039/585 (2013.01); C12N 2760/16121 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16132 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16143 (2013.01); C12N 2760/16151 (2013.01); C12N 2760/16161 (2013.01); C12N 2760/16221 (2013.01); C12N 2760/16222 (2013.01); C12N 2760/16232 (2013.01); C12N 2760/16234 (2013.01); C12N 2760/16243 (2013.01); C12N 2760/16251 (2013.01);
Abstract

The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.


Find Patent Forward Citations

Loading…